Atrix licenses Atrisorb GTR barrier to Block Drug; deal could generate $50 mil. in milestone payments.
This article was originally published in The Gray Sheet
Executive Summary
BLOCK DRUG TO MARKET ATRIX' ATRISORB GTR BARRIER IN U.S. and certain European markets under an agreement announced by the companies Dec. 17. The guided tissue regeneration barrier for the treatment of periodontal disease gained FDA approval in March. Atrix began selling the product in European markets during the first quarter of 1996; the firm commenced U.S. sales in July. The deal will put Atrisorb in the hands of Block's approximately 80 sales reps, who are expected to launch the product in the first quarter of 1997.